CAMKK2

Across TCGA pan-cancer cohorts, CAMKK2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CAMKK2 data layer compared with 21 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CAMKK2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CAMKK2 expression acts as an unfavorable survival marker, although some lineages such as GBM and LSCC show a favorable association.

PDAC, COAD, and GBM are the cancer types where CAMKK2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.454	0.952	.003	49	view →
COAD	DFS	Median	II,III,IV	0.875	1.000	.015	48	view →
GBM	DFS	Quartile	All	0.846	0.613	.018	3	view →
LSCC	OS	Quartile	All	0.958	0.787	.045	2	view →
LUAD	OS	Median	All	0.612	0.868	.017	2	view →
CCRCC	OS	Median	All	0.851	0.932	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CAMKK2–PDAC (OS)

Open the PDAC breakdown →